Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. It develops recombinant protein drugs such as rHuGM-CSF, rHuG-CSF, rHuIL-11, rHuIFN a-2a and rHuIFN a-2b.The company's products include Molgramostim, Filgrastim, and Oprelvekin. Xiamen Amoytop Biotech was founded on August 7, 1996 and is headquartered in Xiamen, China.